Clinical trials: Diabetes Type I
Healthy Volunteers and Diabetes Participants
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.
- Trial name
- NCT07901595
- Testing
- PAL-119
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Paulex Bio Inc.
Diabetes, Diabetes Mellitus, Type 1 Diabetes
Argus 2.0 Adoption Study
This study evaluates the usability of the KOS Argus Continuous Glucose Monitoring (CGM) System, a noninvasive, wrist-worn device that estimates blood glucose levels using light-based sensors and artificial intelligence…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Type 2, Prediabetes
- Trial name
- NCT07425236
- Testing
- KOS Argus Continuous Glucose Monitoring System
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- KOS Inc.
Diabetes Mellitus, Type 2
A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers
The main purpose of this study is to assess the safety and pharmacokinetics of SRT2379 (25, 75, 250, 500, 1000, 2000, and 3000 mg/day [fasted] and 500 mg/day [fed]) in healthy male volunteers.
- Trial name
- NCT01018628
- Testing
- SRT2379
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1, Diabetes Mellitus
Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus
This Phase I clinical trial is a single-center, single-arm, open-label study aimed at evaluating the safety and therapeutic efficacy of RGB-5088 islet cell transplantation in patients with Type 1 Diabetes Mellitus.
- Trial name
- NCT06731218
- Testing
- RGB-5088
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Reprogenix Bioscience, Inc
Healthy Volunteers, Diabetes Mellitus, Type 1
A Study of LY2605541 Versus Insulin Glargine on Blood Sugar
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, what effect this investigational drug has on the…
- Trial name
- NCT01654380
- Testing
- LY2605541, Insulin glargine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypertension, Type 2 Diabetes
Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes
Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit.
- Trial name
- NCT00803660
- Where
- 19 sites in Vietnam
- Volunteers
- 1,060 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Special Survey for Paediatric Subjects
This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using NovoRapid® (insulin aspart) in children with type 1 and type 2 diabetes under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01487382
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 241 people
- Sponsor
- Novo Nordisk A/S
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo.
- Trial name
- Tremelimumab (NCT01843374)
- Testing
- Tremelimumab
- Where
- 104 sites in United States, Australia and 17 more
- Volunteers
- 571 people
- Sponsor
- MedImmune LLC
Treatment of Type I Diabetes Mellitus.
Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
Phase IB will evaluate the safety of autologous, ex vivo-engineered, co-stimulation impaired dendtritic cells to maintain and improve functional residual beta cell mass in new onset Type I Diabetes Mellitus (T1DM) patients.
- Trial name
- NCT01947569
- Testing
- Biological
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- DiaVacs, Inc.
Diabetes Mellitus, Type 1
Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin
Reason for the study The participants have been diagnosed with type 1 diabetes and are being treated with standard insulin therapy.
- Trial name
- NCT07634770
- Testing
- oral insulin, subcutaneous insulin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Diabetes Mellitus, Type 1
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
This study will be conducted in participants with type 1 diabetes mellitus to investigate how the human body processes LY900014, a new blood sugar lowering insulin, and its effect on blood sugar levels when it is delivered via an…
- Trial name
- NCT03056456
- Testing
- LY900014, Insulin Lispro (Humalog)
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes, Type 1, Diabetes, Type 2
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Pulmonary Safety in Diabetics with T/I
- Trial name
- NCT00308737
- Testing
- Technosphere® Insulin Inhalation Powder, Usual Care
- Where
- 176 sites in United States, Canada and 6 more
- Volunteers
- 2,053 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Type 2 Diabetes
To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.
- Trial name
- JMAD (NCT00916604)
- Testing
- AZD1656
- Where
- 2 sites in Japan
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study.
- Trial name
- NCT02402933
- Testing
- Nasal Glucagon
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes
The study is an open-label extension study, offering patients who participated and completed previous study 901 to continue treatment with DiaPep277 and clinical follow-up, for 2 additional years.
- Trial name
- NCT00644501
- Testing
- DiaPep277
- Where
- 3 sites in Israel
- Volunteers
- 43 people
- Sponsor
- Andromeda Biotech Ltd.
Type 1 Diabetes
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus
The purpose of this study is to identify the safest dose of very low dose glucagon to prevent hypoglycemia in patients with Type I diabetes who use insulin pumps and to measure the the amount of glucagon in the blood and see how…
- Trial name
- NCT00304538
- Testing
- very low dose (VLD) glucagon
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- DiObex
Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM)
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 5.
- Conditions
- Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM), Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03174522
- Testing
- REX-001
- Where
- 15 sites in Czechia, Hungary and 4 more
- Volunteers
- 49 people
- Sponsor
- Ixaka Ltd
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure.
- Trial name
- NCT00403481
- Testing
- olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
- Where
- 27 sites in United States
- Volunteers
- 192 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Liver
Safety Study of Pioglitazone Compared To Glyburide on Liver Function
The purpose of this study is to determine the liver safety of pioglitazone, once daily (QD), versus glyburide taken with metformin and insulin.
- Trial name
- NCT00494312
- Testing
- Pioglitazone, Glyburide
- Volunteers
- 2,120 people
- Sponsor
- Takeda
Advanced Solid Malignancies
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.
- Trial name
- STRONG (NCT03084471)
- Testing
- MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
- Where
- 79 sites in United States, Canada and 6 more
- Volunteers
- 867 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.